Nonsteroidal immune-modulating therapies and reduced risk of adverse cardiovascular events in dermatomyositis and polymyositis: A cohort study in the All of Us research program - 24/12/24
Doi : 10.1016/j.jaad.2024.10.075
Jill T. Shah, BA a, Keya T. Shah, DO b, Soutrik Mandal, PhD c, Michael S. Garshick, MD, MS a, d, Alisa N. Femia, MD a, ⁎ 
a Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, New York
b Department of Medicine, NYU Langone Long Island Hospital, Mineola, New York
c Department of Population Health, NYU Grossman School of Medicine, New York, New York
d Leon H. Charney Division of Cardiology, Department of Medicine, New York University Langone Health, New York, New York
∗Correspondence to: Alisa N. Femia, MD, The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, NYU Langone Health, 222 East 41st Street, 16th Floor, New York, NY 10017The Ronald O. Perelman Department of DermatologyNYU Grossman School of MedicineNYU Langone Health222 East 41st Street16th FloorNew YorkNY10017
En prensa. Pruebas corregidas por el autor.
Disponible en línea desde el Tuesday 24 December 2024
Key words : coronary artery disease, dermatomyositis, heart failure, idiopathic inflammatory myositis, immunomodulatory therapy, major adverse cardiac events, myocardial infarction, polymyositis, stroke
| Drs Garshick and Femia contributed equally to this article. |
|
| Funding sources: National Center for Advancing Translational Sciences (NCATS), National Institutes of Health Grant Award Number UL1TR001445. |
|
| IRB approval status: Not applicable. |
© 2024
American Academy of Dermatology, Inc.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?